Boston Scientific Corporation (BSX) Stock Analysis 2026

Boston Scientific is one of the world's largest medical device companies, focused on minimally invasive procedures across cardiology, rhythm management, endoscopy, urology, and neuromodulation. Key products include drug-eluting stents, EP (electrophysiology) catheters for treating heart arrhythmias, intravascular ultrasound (IVUS), and the WATCHMAN device (left atrial appendage closure to prevent stroke in atrial fibrillation patients). The company has transformed from a stent-heavy business to a diversified medical device platform.

This chart shows how Boston Scientific's revenue flows through to profit. Each row deducts a layer of costs: first the direct cost of making products/services (Cost of Revenue), then operating expenses like marketing and R&D, then taxes. What remains at the bottom is net income — the actual profit shareholders own. High gross and net margins indicate a business with strong pricing power and efficiency.

Boston Scientific Corporation trades at a trailing P/E of 18.96x, generates $2.45B in free cash flow, runs a debt/equity ratio of 50.15, and converts shareholder equity into profit at a 15.3% return on equity. For context: P/E ratio measures how much you pay for $1 of earnings (lower = cheaper, but fast-growing companies command higher P/E); Free Cash Flow is the cash left after running the business; Debt/Equity shows how leveraged a company is; Return on Equity shows how efficiently it turns shareholder capital into profit.

Wall Street analysts covering Boston Scientific Corporation currently haven't converged on a clear consensus rating, with a mean 12-month price target of $62.69 (+44.6% vs the current price). Analysts set these targets after researching a company's earnings, competitive position, and industry trends — Strong Buy / Buy means the majority expect meaningful upside, while Hold means fair value near the current price rather than a sell signal.

BSX is currently in a death cross pattern, trading below its 50-day average of $46.63 and below its 200-day average of $67.87. Moving averages smooth out day-to-day volatility to reveal the underlying trend — a Golden Cross (50MA crosses above 200MA) is a classic bullish signal, a Death Cross is bearish, though both are lagging indicators that confirm trends rather than predict them.

BSX's investment case breaks down into 4 bull points and 4 bear points below. The bull case outlines the key reasons the stock could outperform — competitive advantages, growth catalysts, and market tailwinds. The bear case highlights the most significant risks. A strong bull case with manageable bear risks typically makes for a more compelling investment.